Iovance IOVA Rips to $13.64 on a $55M Guidance Raise as Amtagvi Runs 40% Quarter Over Quarter

Iovance Biotherapeutics traded at $13.64 late Tuesday morning, up $2.65 or 24.13%, on 12.97 million shares against a three-month average of 16.6 million, with the session barely two hours old. The stock surged 10.5% in the first minutes of premarket to $12.15, extended to more than 14% as the numbers were digested, opened at a new 52-week high of $11.17, ran from roughly $11.02 at 6:55 a.m. ET to over $13.50 by 9:05 a.m., settled near $12.90 at the open, and pushed to $13.64 by mid-morning. Market cap is $6.18 billion. The stock is up 406% over 52 weeks from a low of $1.76, and it has run from $8.25 on September 11 to $11 by September 25 to $13.64 today, a 65% move in eighteen days.

The catalyst was a Form 8-K filed before the open raising full-year 2026 total revenue guidance to $410 million to $420 million from $350 million to $370 million. The midpoint moved up $55 million, or roughly 15%, to $415 million, which clears the consensus analyst estimate of $402.8 million by $12 million and implies nearly 60% annual revenue growth on a 2025 base of $264 million. The company attributed the raise to sustained and accelerating U.S. demand for Amtagvi, its tumor-infiltrating lymphocyte therapy for advanced melanoma, and for Proleukin, the IL-2 product used in the Amtagvi regimen. The raise completes a guidance review the company announced alongside its record second quarter on August 6, when it said it would update the range "during the third quarter." It updated it on the second-to-last day of the quarter.

The move is not a surprise in direction, only in size. Two sell-side desks had already moved on the stock in the past two weeks: one raised its target to $15 from $13 on September 17, and another resumed coverage with a Buy and a $15 target on September 24, citing an inflection in the Amtagvi launch as logistics smooth out and margins improve. The stock had run 33% into the raise on those calls and on a daily chart that has been grinding higher since the July low. The guidance confirmed what the price was already saying.

The thesis for this forecast: Iovance at $13.64 is a commercial-stage biotech that has crossed from launch risk to execution risk, with a product growing 40% quarter over quarter, gross margin at 56% and rising, a cash runway into the second half of 2028, and a pipeline with two oral presentations at the largest oncology meeting in Europe in four weeks. It trades at roughly 14 times 2026 sales, which is expensive for a company losing $47 million a quarter and cheap for one that just raised guidance 15% with three months left in the year. The $15 sell-side target is 10% away. The real target is what the fourth-quarter NSCLC data and the ESMO presentations do to the 2027 numbers.

The Guidance Math: $415 Million Means $122 Million a Quarter in the Second Half, Up 23% From Q2

The new range implies a specific second-half trajectory. First-half 2026 revenue was $170.7 million, with $71.4 million in the first quarter and a record $99.3 million in the second. The midpoint of $415 million leaves $244 million for the second half, or roughly $122 million per quarter. That is a 23% step up from the second quarter's $99.3 million, and it implies a fourth quarter above $125 million if the third quarter comes in at the Q2 run-rate plus modest growth. The low end of the range at $410 million implies $120 million a quarter; the high end at $420 million implies $125 million.

For context, the company's own history says those numbers are achievable. Second-quarter revenue grew 39% sequentially from the first quarter and 66% year over year. U.S. Amtagvi revenue was $91 million in the second quarter, up 40% from the fourth quarter of 2025. Fourth-quarter 2025 Amtagvi revenue was about $65 million, and full-year 2025 Amtagvi revenue was about $220 million. A product that went from $65 million to $91 million in two quarters does not need to accelerate to hit $110 million by the fourth quarter; it needs to hold its pace. The Proleukin line at $9 million in the second quarter is expected to grow through the remainder of 2026 as more Amtagvi patients require the IL-2 component.

The margin trajectory matters as much as the revenue. Gross margin was 56% in the second quarter, up from roughly 50% in the fourth quarter of 2025, on higher Amtagvi volume, continued cost optimization, and maturing internal manufacturing efficiencies. Cost of sales fell to $43.6 million in the second quarter from $48.9 million a year earlier even as revenue rose 66%, which is what operating leverage in a cell therapy business looks like once the manufacturing facility is internalized and running at scale. The company said improvements in gross margin are expected to continue, excluding one-time items. A 60% gross margin on $122 million of quarterly revenue is $73 million of gross profit against roughly $98 million of operating expenses, which narrows the operating loss to $25 million per quarter from $52 million in the second quarter.

That is the path to profitability that the guidance raise implies, and it is the reason the stock gapped 24% rather than 10%. A $55 million revenue raise at a 56% gross margin is $31 million of incremental gross profit, and with operating expenses falling, most of it drops to the operating line. The company has not guided to profitability, but the second-half implied run-rate puts breakeven within reach in 2027 without any pipeline contribution. Third-quarter results land in early November, and the number that will decide whether the stock holds $13 is whether Q3 revenue prints above $115 million.

The Second Quarter That Set This Up: $99.3 Million, 56% Gross Margin, and a Net Loss That Halved

The second-quarter 8-K filed August 6 is the foundation of today's move. Total product revenue was $99.3 million, up 66% from $60.0 million in the second quarter of 2025 and 39% from $71.4 million in the first quarter of 2026. U.S. Amtagvi revenue was approximately $91 million. Global Proleukin revenue was approximately $9 million. Gross margin excluding depreciation and amortization was 56%. Research and development expenses were $58.9 million, down 6% from the first quarter in the fourth consecutive quarter of improvement and down from $77.9 million a year earlier. Selling, general and administrative expenses were $39.3 million, up modestly from $37.6 million as the sales team expanded.

The loss from operations was $51.9 million, less than half the $113.8 million loss a year earlier. Net loss was $47.3 million, or $0.11 per share, against $111.7 million, or $0.33 per share, in the second quarter of 2025. For the first half, net loss was $126.4 million against $227.8 million a year earlier. Weighted average shares outstanding were 450.2 million in the quarter, up from 334.5 million a year earlier, reflecting the equity raises that funded the launch. Non-cash stock-based compensation was $11.7 million in the quarter.

The balance sheet is the part that removes the financing risk. Cash, cash equivalents and investments were $297.7 million at June 30, plus $6.0 million of restricted cash, for a cash position of approximately $304 million. The company said current cash is expected to fund operations into the second half of 2028. Total assets were $915.5 million, total liabilities roughly $179.5 million, long-term debt about $43.3 million, and stockholders' equity $736.0 million. The current ratio is 4.4 and working capital is roughly $357 million. A biotech with two years of runway, a product growing 40% a quarter, and a gross margin above 50% does not need to raise equity, and the absence of dilution risk is part of why the stock can re-rate on a guidance raise.

The operating detail that matters for the forecast is the demand driver. Record Amtagvi demand was catalyzed by a new marketing campaign and an expanded sales team, driving adoption across a growing authorized treatment center network and referrals toward earlier treatment. Unaided physician awareness of Amtagvi nearly tripled over the past year. Real-world studies by Iovance and treatment centers report objective response rates of 50% or greater on commercial product, which is above the rates in the pivotal trial and is the single most important number for a cell therapy launch: when the real-world data beats the trial data, referrals accelerate.

The Commercial Engine: 100 Treatment Centers, 110 by Year-End, and a 31-Day Turnaround

Amtagvi is a one-time autologous cell therapy, which means each dose is manufactured from the patient's own tumor tissue. That creates a commercial model unlike a pill: the constraint is not prescriptions but the number of authorized treatment centers that can harvest tumor tissue, ship it to Iovance's manufacturing facility, and infuse the returned product. The authorized treatment center network has grown to approximately 100 U.S., Canadian and Australian sites, up from more than 95 at the time of the second-quarter report, and the company remains on track for at least 110 active centers by the end of 2026. Community centers now represent a third of the network and are expected to increase significantly over the next several quarters, which is the shift from academic medical centers to the broader oncology market that every cell therapy needs to scale.

Manufacturing turnaround time is 31 days or less, using what the company describes as the only scaled, centralized commercial manufacturing process approved by the FDA for TIL therapy. That number is the operational bottleneck for a therapy given to patients with advanced disease: a 31-day turnaround is fast enough that most patients who begin the process complete it. Iovance internalized all lifileucel manufacturing during 2025, and the gross margin improvement from roughly 50% to 56% is the direct result. The company said it is deploying AI tools to drive further cost efficiencies.

The addressable market in the approved indication is finite. Amtagvi is approved for previously treated advanced melanoma, a population of several thousand patients per year in the United States. At roughly $515,000 per treatment, $91 million of quarterly revenue represents fewer than 200 patients infused per quarter, which means penetration of the eligible population remains in the low double digits. The runway inside the current label is measured in years, and the guidance raise reflects the company's view that penetration is accelerating, not that it is approaching a ceiling.

The international expansion is incremental. Amtagvi was approved in Canada in August 2025 and in Australia by the Therapeutic Goods Administration in the second quarter of 2026, its third global approval; Australian centers are being authorized in parallel with national reimbursement discussions. The U.K. marketing authorization application was resubmitted in early July and is under expedited review by the MHRA for potential approval later in 2026. Switzerland is expected in the first half of 2027, and the European Medicines Agency resubmission is on track for 2027. None of those markets contribute meaningfully to 2026 revenue, and all of them are upside to the 2027 numbers that the sell-side has not yet modeled.

The Pipeline: NSCLC in Q4, Two ESMO Orals in October, and a Frontline Interim That Could Reset the Label

The reason Iovance trades at 14 times sales rather than 6 is the pipeline, and it has three dates in the next 90 days. First, the European Society for Medical Oncology annual meeting in Madrid runs October 23 to 27, and Iovance has two oral presentations. Abstract #3725RO covers the SARATOGA registrational trial in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, where early data showed a 50% objective response rate by RECIST v1.1 in the first six evaluable patients and earned FDA Fast Track Designation. Abstract #2072O covers TILVANCE-301, the Phase 3 randomized trial of lifileucel plus pembrolizumab in frontline advanced melanoma, with results supporting the combination as a potential best-in-class frontline option.

Second, the IOV-LUN-202 program in previously treated metastatic non-squamous non-small-cell lung cancer has program updates expected in the fourth quarter. Enrollment is nearly complete in the pivotal cohorts, the initial results supported FDA Fast Track Designation, and a supplemental Biologics License Application is planned for 2027. The company estimates the U.S. market opportunity in metastatic non-squamous NSCLC at about seven times that of advanced melanoma. That single line is the bull case in one sentence: a positive lung cancer readout in the fourth quarter converts a $415 million melanoma franchise into a platform with a multi-billion-dollar second indication.

Third, TILVANCE-301 includes an early interim analysis based on objective response rate for a potential sBLA in frontline advanced melanoma. The trial also serves as the confirmatory study for Amtagvi's accelerated approval in second-line disease. A positive interim would move Amtagvi from a second-line therapy given after checkpoint inhibitor failure to a frontline combination, which expands the eligible population several-fold and removes the regulatory overhang of an accelerated approval that has not yet been confirmed.

Behind those three are the next-generation programs: IOV-4001, a PD-1-inactivated TIL in Phase 1/2 for melanoma and NSCLC; IOV-5001, an IL-12-tethered TIL for colorectal, triple-negative breast and other cold tumors; IOV-3001, a modified IL-2 designed to replace Proleukin with a lower-toxicity regimen; a serous endometrial cancer program with an expedited pathway under discussion with the FDA; and investigator-sponsored trials in cutaneous squamous cell and Merkel cell carcinoma with data in the first half of 2027. The company holds more than 400 granted or allowed patents with exclusivity through at least 2042. None of it is in the $415 million guide. All of it is in the $6.18 billion market cap.

Valuation: 14 Times Sales for 60% Growth, or a $6 Billion Bet on Lung Cancer?

Iovance at $13.64 with 450 million weighted shares has a market cap of $6.18 billion. Net of $304 million in cash and $43 million of debt, enterprise value is roughly $5.9 billion. On the new 2026 guidance midpoint of $415 million, that is 14.3 times enterprise value to sales. On the consensus 2027 estimate, which sat near $550 million before today and will move higher, it is roughly 10.7 times. On a 2028 number that assumes NSCLC approval in late 2027 and a frontline melanoma label, the multiple falls to mid-single digits, which is why the sell-side targets at $15 are described as conservative by the desks that hold them.

The comparison set is commercial-stage cell therapy and oncology launches. The CAR-T companies that reached $400 million to $500 million in annual revenue during their launch years traded between 8 and 20 times sales depending on pipeline breadth, and the ones with a credible second indication traded at the top of that range. Iovance at 14 times is in the middle. It has a first-in-class product with no direct competitor in TIL therapy, a 56% gross margin that is heading toward 60%, and a pipeline with two Fast Track designations beyond the approved label. It also has a net loss of $47 million a quarter, an interim CEO, and a stock that has been through a securities class action and a 70% drawdown within the past 18 months.

The bear case on valuation is that $6.18 billion prices a lung cancer approval that has not happened. The IOV-LUN-202 program is a single-arm trial in a heavily pretreated population, and the FDA's willingness to grant accelerated approval on single-arm data in NSCLC is not guaranteed. If the fourth-quarter update shows response rates below 25% or durability that does not hold, the stock loses the seven-times-melanoma multiple and reverts to a melanoma-only valuation, which at 8 times the $415 million guide is $3.3 billion, or roughly $7.40 per share. That is 46% downside from today's price, and it is the number the short sellers are working from.

The bull case on valuation is that the company does not need lung cancer to grow into the multiple. Melanoma alone, with 110 centers, real-world response rates above 50%, expanding community penetration, U.K. and Swiss approvals in the next nine months, and a frontline label from TILVANCE-301, supports $700 million to $900 million in revenue by 2028. At a 60% gross margin and $400 million of operating expenses, that is $100 million to $150 million of operating profit, and a profitable cell therapy company with a platform trades at 25 to 30 times earnings. Twenty-five times $130 million is $3.25 billion of value on melanoma alone, and everything else is the option.

Technicals: $11.17 Is the Gap Floor, $13.50 Is the Intraday Pivot, $15 Is the Target, $8.25 Is the September Base

The chart is a breakout on a gap, and gaps on guidance raises have a specific behavior: they either hold and extend, or they fill within three sessions and the stock spends a month rebuilding. Support first. $13.50 is the level the stock hit at 9:05 a.m. and the intraday pivot; a hold above it through the close confirms the gap. $12.90 is where the stock settled at the open after the initial spike, and it is the first level buyers defended. $12.15 is the premarket print after the first 10.5% pop. $11.17 is the opening price and the new 52-week high, and it is the floor of the gap: a close below it fills the gap and invalidates the breakout. $11.00 is where the stock traded from September 25 through Monday's close, and it is the base the gap launched from. $10.02 is the strike on inducement stock options granted to 18 new hires, which is the level management set as the bar for its own compensation. $8.25 is the September 11 low and the start of the current leg. $5.63 is the level that was the 52-week high as recently as April. $1.76 is the 52-week low.

Resistance next. $13.64 is Tuesday's print and the level to reclaim on any afternoon dip. $14.00 is the round number and the first target above the intraday high. $15.00 is the target on two sell-side desks and the psychological level, 10% above the current price. $16.50 is the 20% extension of the gap move. $18.00 is the level the stock last traded at in the summer of 2024 before the class action and the drawdown. $20.00 is the round number and roughly where a successful NSCLC readout would put the stock on a $9 billion market cap.

The daily chart has been grinding higher since the July low with a series of higher lows: $8.25 on September 11, $9.50 on September 18, $11.00 on September 25. The 50-day moving average is near $9.30 and the 200-day is near $6.80, and the stock is now more than 45% above the 50-day, which is the kind of extension that produces a consolidation. Daily RSI printed above 80 at the open, which is overbought by any definition. Volume at 12.97 million shares two hours into the session is on pace for 40 million on the day, more than double the average, which is the volume a gap needs to hold.

The pattern is a breakout from a three-week base at $11 on a fundamental catalyst with elevated volume. Gaps of this type on guidance raises fill less than 30% of the time when the raise beats consensus by more than 2%, and this one beat by 3%. The bias is long above $11.17 with a target at $15 and a stop below $11. A close below $11.17 flips the bias to a gap-fill trade with a target at $10.

The Sector Backdrop: Biotech Is the One Place Money Is Going in a 5.26% World

Iovance is not alone. The most-active and top-gainer lists Tuesday are dominated by biotech and specialty pharma: Iovance up 24.13%, Summit Therapeutics up 7.17% to $16.59 on 10.97 million shares, Kodiak Sciences up 177.96% on Monday on a Phase 3 readout, AbCellera up 9.61%, ADMA Biologics up 7.89%, Liquidia up 7.66%, MBX Biosciences up 7.29%, Abivax up 6.36%, Definium Therapeutics up 6.19%, Nektar up 5.85%, PTC Therapeutics up 5.23%. The sector is catching a bid on a day when the S&P 500 is flat at 7,681, the Nasdaq is flat at 26,826, and the 10-year Treasury is at 5.264%.

That is unusual, and it says something about where the marginal dollar is going. High-multiple, long-duration growth is getting sold on the rate shock: Arm dropped 8.70% Monday, Credo fell 8.67%, Qualcomm lost 7.17%, and the AI builders are being liquidated on OpenAI's second training pause. Biotech with commercial revenue and binary catalysts is being bought, because the return on a positive Phase 3 or a guidance raise does not depend on the discount rate. A 24% one-day move in a $6 billion stock is not a rates trade. It is a fundamentals trade, and fundamentals trades are the only ones working in a market where the Fed is hiking.

The health care sector was one of only three S&P 500 sectors to close higher on Monday, alongside consumer staples and energy, and Waters, Agilent and Biogen all hit new highs. The defensive bid in large-cap health care and the speculative bid in small-cap biotech are the same trade from different angles: both are bets that earnings tied to patients rather than to capex cycles hold up when the capex cycle cracks. Iovance sits at the intersection, with a product growing 40% a quarter and a pipeline of binary events.

The risk in the sector read is that it reverses fast. Biotech is the highest-beta sector in the market, and a day when the Nasdaq loses 2% on a hot PCE print is a day when the XBI loses 4% and Iovance loses 8% regardless of the guidance. The stock's 406% 52-week gain was built in a market that has been more forgiving to small caps than it is today, and a 24% gap in a $6 billion name attracts profit-taking from every holder who bought under $8. The sector tailwind is real for now, and it lasts exactly as long as the next inflation print allows.

What Changed Since 2025: A Class Action, a $1.64 Low, an Interim CEO, and a Turnaround Nobody Believed

The stock's history is the reason the guidance raise produced a 24% move rather than a 10% one. Eighteen months ago Iovance was a launch story that was failing. Amtagvi was approved in February 2024, the initial launch was slower than guided, the company missed its own early revenue targets, a securities class action was filed in 2025 over the launch disclosures, the CEO departed and was replaced on an interim basis, and the stock fell from above $18 to a 52-week low of $1.64 in April 2026, a 91% drawdown. As recently as the July 2025 run-up, the stock was described as being in a "free fall" with short interest rising significantly and trading on speculation rather than news.

What changed is that the launch worked. Fourth-quarter 2025 revenue grew roughly 30% quarter over quarter and the company achieved its full-year 2025 guidance of $250 million to $270 million with $264 million. First-quarter 2026 revenue was $71.4 million. Second-quarter revenue was $99.3 million, a 39% sequential jump. The authorized center network went from a few dozen to nearly 100. Manufacturing was internalized and gross margin went from below 40% to 56%. R&D fell for four consecutive quarters. The net loss halved. And the company, which had been criticized for over-promising in 2024, under-promised in 2026: it guided $350 million to $370 million in February, watched the second quarter blow through the run-rate, said it would review, and then raised by $55 million.

That sequence is why the stock has 406% of 52-week gains and why the short interest that built through the drawdown is now fuel. A stock that was left for dead at $1.64 with heavy short positioning and then delivered four consecutive quarters of sequential growth, a gross margin inflection, and a guidance raise is a stock in which every short is underwater and every early long is sitting on a multi-bagger. The 24% gap is partly the fundamentals and partly the positioning: shorts covering into a guidance raise they did not expect, and longs who bought at $2 deciding that $13 is not yet the place to sell.

The interim CEO question is the one unresolved corporate item. The current chief executive has been interim since the 2025 transition and has overseen the turnaround; the board has not named a permanent successor. A permanent appointment, or the removal of "interim" from the current title, would be a small positive. A surprise external hire would introduce uncertainty at exactly the wrong moment. The company's conference appearances this fall are the venue to watch for any signal.

Bull Case: Hold $12.90, Beat Q3, Positive ESMO, Positive NSCLC, Target $18–$20

The bull case starts with what the guidance raise proved. Amtagvi demand is accelerating, not plateauing, 30 months into launch. The $415 million midpoint implies $122 million per quarter in the second half, a 23% step up from the record second quarter, and the company has beaten its own trajectory in every quarter since the fourth quarter of 2025. Gross margin is at 56% and rising. Operating expenses are falling. Cash of $304 million funds operations into the second half of 2028 with no equity raise required. The authorized center network grows to 110 by year-end with community centers taking share. U.K. approval is expected later in 2026 and Swiss approval in the first half of 2027.

The trigger sequence is three events in ten weeks. First, the ESMO orals on October 23 to 27: a SARATOGA presentation that holds the 50% response rate in a larger sarcoma cohort, and a TILVANCE-301 presentation that supports frontline lifileucel plus pembrolizumab as best-in-class, each worth $1 to $2 on the stock. Second, third-quarter results in early November: a print above $115 million with gross margin above 57% confirms the second-half run-rate and takes the stock to $15. Third, the IOV-LUN-202 program update in the fourth quarter: response rates above 25% with durable responses in the pivotal cohorts confirm the 2027 sBLA path in an indication seven times the size of melanoma, and the stock re-rates toward a platform multiple.

The path is $13.50 held through Tuesday's close, $14 by the end of the week, $15 into ESMO, $16.50 on a Q3 beat, and $18 to $20 on a positive lung cancer update. The upside from $13.64 to $15 is 10%; to $18 it is 32%; to $20 it is 47%. The $20 level is roughly a $9 billion market cap, which is 16 times a 2027 revenue estimate near $560 million and a reasonable multiple for a company on a credible path to two approved indications and profitability.

The structural argument is that TIL therapy has no direct competitor. Iovance is the first and only company to take TIL from concept to a broadly accessible commercial product, it owns the only FDA-approved scaled manufacturing process, and it holds patents through 2042. Every additional indication is incremental revenue on a fixed manufacturing base with a rising gross margin. That is the definition of a platform, and platforms in oncology with positive real-world data compound.

Bear Case: Gap Fills to $11, Q3 Misses the Run-Rate, NSCLC Disappoints, Target $8

The bear case starts with the price. Iovance is up 65% in eighteen days, 24% today, 406% over 52 weeks, and more than 45% above its 50-day moving average with a daily RSI above 80. That is the most extended the stock has been since the April 2024 launch, and extensions of that size in $6 billion biotechs revert. Every holder who bought under $8 in the summer is sitting on a gain that a 24% gap invites them to take. A guidance raise that beats consensus by 3% is a good number, not a transformational one, and the market has priced it as transformational.

The trigger is a close below $12.90, the level the stock settled at on the open, followed by a close below $11.17, the gap floor. That fills the gap, invalidates the breakout, and puts the stock back in the $11 base with the September 11 low at $8.25 as the next support. From there the question is whether the third-quarter print in early November holds the implied run-rate. If Q3 revenue comes in below $110 million, the $415 million midpoint requires a fourth quarter above $135 million, which the market will not believe, and the stock trades to $10.

The fundamental risk is the pipeline. The fourth-quarter IOV-LUN-202 update is a single-arm trial in a pretreated NSCLC population, and if response rates come in below 20% or the duration of response is short, the seven-times-melanoma opportunity evaporates and the stock reverts to a melanoma-only valuation. At 8 times the $415 million guide that is $3.3 billion, or $7.40 per share, 46% below today. The ESMO presentations carry similar binary risk: a sarcoma cohort that regresses from 50% to 30% or a TILVANCE interim that does not clear the bar for an sBLA would each cost the stock $2 to $3.

The corporate risks are the interim CEO with no permanent successor named, a securities class action from 2025 that is still working through the courts, and a shareholder base that has been through a 91% drawdown and may not have the patience for a second one. The macro risk is that biotech is the highest-beta sector in a market where the 10-year is at 5.264% and the Fed is priced for an October hike; a hot PCE Wednesday takes the XBI down 3% and Iovance down 6% on no news. The downside from $13.64 to the gap fill at $11.17 is 18%; to the September base at $8.25 it is 40%. The bear case is a 35% probability, and most of it is the price, not the business.

What to Watch: The Close Today, Wells Fargo and Wainwright Conferences, ESMO Oct 23, Q3 in Early November

The first test is Tuesday's close. A gap of this size on a guidance raise is confirmed by a close in the upper half of the day's range, which means above $12.90 at minimum and ideally above $13.50. Volume on pace for 40 million shares against a 16.6 million average is the right profile. A close below $12.15, the first premarket print, would be a warning that the initial buyers are being sold to.

The near-term calendar is conference season. Iovance is scheduled to present at the Wells Fargo and H.C. Wainwright healthcare conferences this fall, which puts management in front of institutional investors within days of the guidance raise. Institutional ownership stands at 63.4%, and the desks that raised targets to $15 in September will use the conferences to update their models for the new guide. A permanent CEO announcement at either venue would be a small positive. New color on the U.K. MHRA timeline, the Australian reimbursement process, or the pace of community center adoption is the operational detail the stock needs.

The medium-term calendar is ESMO in Madrid from October 23 to 27, with two oral presentations on the sarcoma and frontline melanoma programs. Oral presentations at ESMO are reserved for data the program committee considers practice-relevant, and both abstracts have already been accepted, which removes the risk of a rejection but not the risk of the data underwhelming on presentation. Third-quarter results follow in early November, and the fourth-quarter IOV-LUN-202 update closes the year. Any one of those four events can move the stock 15% in either direction.

The macro calendar is the same as everything else this week: core PCE Wednesday, payrolls Friday, and the Fed on October 28. Iovance does not trade on rates, but the XBI does, and the XBI is the tide. A soft PCE that takes the 10-year toward 5.10% is worth 3% to the sector and 5% to Iovance through the beta. A hot one is worth the same in reverse. The stock's positioning, with a 24% gap and shorts covering, produces sharp moves on any tape change.

Verdict: Buy Above $11.17 With a $15 Target, Add on a Q3 Beat, Stop Below $11

Iovance at $13.64 is a buy for a trade to $15 and a hold for investors who own it and can absorb a gap-fill. The company just raised full-year revenue guidance by $55 million at the midpoint to $410 million to $420 million, cleared consensus by $12 million, and implied nearly 60% annual growth on a product whose gross margin has risen from roughly 50% to 56% in two quarters while R&D fell for four consecutive quarters and net loss halved. It has $304 million of cash funding operations into the second half of 2028, roughly 100 authorized treatment centers on the way to 110, a 31-day manufacturing turnaround, real-world response rates above 50%, and a pipeline with two ESMO oral presentations in four weeks and a lung cancer update in the fourth quarter in an indication seven times the size of the approved one. Two sell-side desks have $15 targets that were set before the raise.

The reasons for caution are the price and the calendar. The stock is up 65% in eighteen days, 24% today, and 406% over 52 weeks, trading 45% above its 50-day moving average with a daily RSI above 80. It is a $6.18 billion company losing $47 million a quarter, run by an interim CEO, that has been through a 91% drawdown and a class action within the past 18 months. It trades at 14 times 2026 sales on the new guide, a multiple that prices a successful NSCLC readout that has not happened, and the readout is a single-arm trial in a heavily pretreated population. And it sits in the highest-beta sector in a market where the Fed is priced for an October hike and the 10-year is at 5.264%.

The forecast: Iovance holds $12.90 through Tuesday's close and consolidates between $12.50 and $14.50 through the conference season, with the gap floor at $11.17 the level that has to hold. A third-quarter print above $115 million in early November takes the stock to $15 and the sell-side targets move to $18. The ESMO presentations on October 23 to 27 are the first binary; a clean showing adds $1 to $2. The fourth-quarter lung cancer update is the second and larger binary; a positive result targets $18 to $20 by year-end, a 32% to 47% gain, and a negative one targets $8, a 40% loss. The base case is $15 to $16 by mid-November on the Q3 print alone, a 10% to 17% gain.

The trade is long from $12.90 to $13.60 with a stop below $11, a first target at $15, and a second at $16.50, adding on a Q3 beat and reducing into the fourth-quarter NSCLC readout unless the position is sized for a binary. The reward-to-risk on the first target is roughly 1-to-1 from here and 2-to-1 from a pullback to $12.50, which is where the entry is better. Iovance has done the hard part: it built a commercial cell therapy business from a failed launch, and it just proved the demand is accelerating. The next 90 days decide whether it is a $400 million melanoma company or a multi-indication platform, and the market at $13.64 is leaning toward the second answer.